Clinigen Group (OTCMKTS:CLIGF) Upgraded by Zacks Investment Research to “Buy”

Clinigen Group (OTCMKTS:CLIGF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $8.50 price target on the stock. Zacks Investment Research‘s price target points to a potential upside of 10.39% from the company’s current price.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of CLIGF stock remained flat at $$7.70 on Wednesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.32 and a current ratio of 1.54. The firm’s 50 day simple moving average is $7.70 and its 200-day simple moving average is $7.81. The company has a market cap of $942.48 million, a PE ratio of 9.51 and a beta of 0.73. Clinigen Group has a 1-year low of $6.00 and a 1-year high of $12.30.

About Clinigen Group

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines.

Featured Article: Profit margin is different from the revenue

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.